Skip to main content

Advertisement

Table 2 Heart rate limiting drugs in groups (case: beta-blockers, control: non-beta-blockers)

From: The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit

  Case, n = 74 Control, n = 114 p
Previous HRLD use, n (%) 31(41.9) 57 (50.0) 0.28
Previously used HRLDs
 Beta-blocker, n (%) 27 (87.1) 4 (7.0) 0.001
 Diltiazem, n (%) 1 (1.4) 37 (64.9)
 Amiodorone, n (%) 0 (0.0) 2 (3.5)
 Digitoxin, n (%) 0 (0.0) 3 (5.3)
 Multidrug*, n (%) 3 (12.9) 11 (19.3)
HRLDs used in ICU
HRLD, n Metoprolol = 59 Diltiazem = 91 --
Bisoprolol = 4 Digoxin = 2
Carvedilol = 11 Amiodorone = 3
  *More than one =18
Reasons for HRLD use, n(%)    
 AF 17 (23.0) 35 (50.7) 0.004
 SVT 31 (41.9) 62 (54.4)
 VT 0 (0.0) 1 (0.9)
 CHF 13 (17.6) 5 (4.4)
 HT 6 (8.1) 10 (8.8)
 Suspicion of MI 7 (9.5) 1 (0.9)
Only received HRLDs on day 1, n (%) 4 (5.4) 13 (11.4) 0.16
Intermittent HRLD use, n (%) 7 (9.5) 11 (9.6) 0.97
♦Heart rate/min on admission to ICU 111 (21) 115 (25) 0.31
♦Highest heart rate/min 128 (25) 133 (20) 0.14
♦MAP, mmHg on admission of ICU 97 (26) 101 (25) 0.33
♦Highest MAP, mmHg 118 (20) 119 (21) 0.63
  1. *More than one drug used (ie: diltiazem ± digitoxin ± amiadorone). AF, atrial fibrillation; CHF, congestive heart failure, HRLD, heart-rate limiting drug; HT, hypertension, ICU, intensive care unit; MAP, mean arterial pressure; MI, myocardial infarction, SVT, supraventricular tachycardia; VT, ventricular tachycardia. mean (± standard deviation).